logo
Plus   Neg
Share
Email

BD Gets Pre-market Approval From FDA For BD Onclarity HPV Assay

Becton, Dickinson and Co. (BDX) or BD said that it has received pre-market approval from the U.S. Food and Drug Administration for the BD Onclarity HPV assay.

The test detects 14 types of high-risk human papillomavirus (HPV) from specimens collected for cervical cancer screening or "Pap test" in the BD SurePath liquid based cytology vial.

The BD Onclarity HPV assay also identifies HPV genotypes 16, 18, and 45, which are associated with the majority of cervical cancers worldwide, and are disproportionally responsible for up to 94 percent of glandular cervical cancer cases.

BD plans to seek approval in future submissions for reporting of HPV types beyond 16, 18 and 45 consistent with the extended genotyping capabilities of the assay's design and aligned with evolving cervical cancer screening guidelines.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Zynga Inc. (ZNGA), a social game developer, Tuesday said it has inked a multi-year deal with Disney to develop and publish a new "Star Wars" mobile game. Shares of Zynga is currently up nearly 8 percent, following the news. As a part of the agreement, Zynga will also assume operation of the live service... Furniture maker La-Z-Boy Inc. (LZB), Tuesday reported a profit and revenues for the first quarter that trounced Wall Street estimates, sending its shares surgtin about 20 percent in after-hours trade. Monroe, Michigan-based La-Z-Boy's first-quarter profit rose to $18.3 million or $0.39 per share from... Shares of Keysight Technologies Inc. (KEYS) are up 12 percent on extended session on Tuesday after the company's earnings and revenues for the third quarter trumped Wall Street expectations and outlook for the current quarter also exceeded estimates. Santa Rosa, California-based Keysight Technologies...
Follow RTT